Form 4: Akoya Biosciences CEO Brian McKelligon Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Akoya Biosciences' CEO, Brian McKelligon, exercised stock options and sold 7,500 shares of common stock under a pre-arranged 10b5-1 trading plan.
Summary
- On June 11, 2024, Brian McKelligon, the President and CEO of Akoya Biosciences, exercised an option to purchase 7,500 shares of common stock at a price of $0.303 per share.
- Simultaneously, McKelligon sold 7,500 shares of Akoya Biosciences common stock at a weighted average price of $2.084 per share, with individual sales prices ranging from $2.04 to $2.16.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on August 16, 2023.
- Following these transactions, McKelligon directly owns 224,733 shares of Akoya Biosciences common stock and holds options to purchase 275,629 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reflects routine insider trading activity under a pre-arranged plan. There's no indication of positive or negative implications for the company's performance.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The sale represents a small percentage of McKelligon's holdings.
Key Dates
| Date | Description |
|---|---|
| August 16, 2023 | Date of adoption of Rule 10b5-1 trading plan. |
| June 11, 2024 | Date of stock option exercise and share sale. |
| June 12, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.